Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$63.64 - $125.14 $44.7 Million - $87.9 Million
702,300 Added 38.7%
2,516,800 $168 Million
Q2 2024

Aug 14, 2024

SELL
$101.21 - $166.61 $33.6 Million - $55.3 Million
-331,700 Reduced 15.46%
1,814,500 $215 Million
Q1 2024

May 15, 2024

SELL
$85.37 - $115.44 $16.5 Million - $22.3 Million
-192,900 Reduced 8.25%
2,146,200 $229 Million
Q4 2023

Feb 14, 2024

SELL
$69.51 - $104.43 $24.4 Million - $36.7 Million
-351,200 Reduced 13.05%
2,339,100 $233 Million
Q3 2023

Nov 14, 2023

BUY
$96.41 - $126.61 $80.3 Million - $105 Million
832,700 Added 44.83%
2,690,300 $278 Million
Q2 2023

Aug 14, 2023

SELL
$118.5 - $160.53 $5.59 Million - $7.58 Million
-47,200 Reduced 2.48%
1,857,600 $226 Million
Q1 2023

May 15, 2023

SELL
$135.66 - $197.02 $325 Million - $471 Million
-2,392,200 Reduced 55.67%
1,904,800 $293 Million
Q4 2022

Feb 14, 2023

BUY
$118.38 - $210.04 $265 Million - $471 Million
2,241,900 Added 109.09%
4,297,000 $772 Million
Q3 2022

Nov 14, 2022

BUY
$118.07 - $194.18 $28.1 Million - $46.2 Million
237,800 Added 13.09%
2,055,100 $243 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.